D
Donald C. Lo
Researcher at National Institutes of Health
Publications - 13
Citations - 575
Donald C. Lo is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Drug development & Drug discovery. The author has an hindex of 8, co-authored 13 publications receiving 288 citations.
Papers
More filters
Journal ArticleDOI
RNA-Dependent RNA Polymerase as a Target for COVID-19 Drug Discovery.
TL;DR: This review focuses on biochemical enzyme and cell-based assays for RdRPs that could be used in high-throughput screening to discover new and repurposed drugs against SARS-CoV-2.
Posted ContentDOI
An OpenData portal to share COVID-19 drug repurposing data in real time
Kyle R. Brimacombe,Tongan Zhao,Richard T. Eastman,Xin Hu,Ke Wang,Mark Backus,Bolormaa Baljinnyam,Catherine Z. Chen,Lu Chen,Tara Eicher,Marc Ferrer,Ying Fu,Kirill Gorshkov,Hui Guo,Quinlin M Hanson,Zina Itkin,Stephen C. Kales,Carleen Klumpp-Thomas,Emily M. Lee,Sam Michael,Tim Mierzwa,Andrew Patt,Manisha Pradhan,Alex Renn,Paul Shinn,Jonathan H. Shrimp,Amit Viraktamath,Kelli M. Wilson,Miao Xu,Alexey V. Zakharov,Wei Zhu,Wei Zheng,Anton Simeonov,Ewy Mathé,Donald C. Lo,Matthew D. Hall,Min Shen +36 more
TL;DR: The National Center for Advancing Translational Sciences (NCATS) has developed an online open science data portal for its COVID-19 drug repurposing campaign – named OpenData – with the goal of making data across a range of SARS-CoV-2 related assays available in real-time.
Journal ArticleDOI
The SARS-CoV-2 Cytopathic Effect Is Blocked by Lysosome Alkalizing Small Molecules.
Kirill Gorshkov,Catherine Z. Chen,Robert Bostwick,Lynn Rasmussen,Bruce Nguyen Tran,Yu-Shan Cheng,Miao Xu,Manisha Pradhan,Mark J. Henderson,Wei Zhu,Eunkeu Oh,Kimihiro Susumu,Mason A. Wolak,Khalida Shamim,Wenwei Huang,Xin Hu,Min Shen,Carleen Klumpp-Thomas,Zina Itkin,Paul Shinn,Juan Carlos de la Torre,Anton Simeonov,Sam Michael,Matthew D. Hall,Donald C. Lo,Wei Zheng +25 more
TL;DR: In this article, the authors evaluated six lysosomotropic compounds to identify an alternative Lysosome-based drug repurposing opportunity and found that six of these compounds blocked the cytopathic effect of SARS-CoV-2.
Journal ArticleDOI
Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2
Catherine Z. Chen,Paul Shinn,Zina Itkin,Richard T. Eastman,Robert Bostwick,Lynn Rasmussen,Ruili Huang,Min Shen,Xin Hu,Kelli M. Wilson,Brianna M. Brooks,Hui Guo,Tongan Zhao,Carleen Klump-Thomas,Anton Simeonov,Samuel G. Michael,Donald C. Lo,Matthew D. Hall,Wei Zheng +18 more
TL;DR: In this article, the authors carried out a quantitative high-throughput screen using a SARS-CoV-2 cytopathic assay with a compound collection of 8,810 approved and investigational drugs, mechanism-based bioactive compounds, and natural products.
Journal ArticleDOI
Induced pluripotent stem cells for neural drug discovery.
Atena Farkhondeh,Rong Li,Kirill Gorshkov,Kevin G. Chen,Matthew Might,Steven Rodems,Donald C. Lo,Wei Zheng +7 more
TL;DR: Application of iPSC-derived human neurons is a new direction for neuronal drug discovery because these cells have the genetic backgrounds of patients that more precisely model disease-specific pathophysiology and phenotypes.